AgingResearch.NewsJoin free
Research Square

Blood markers linked to risk in cardiovascular-kidney-metabolic stage 2

Six-year risk of cardiovascular disease or death was 15.9% with lower levels of a heart-strain marker versus 44.0% with higher levels.

Paper by Sirui Sun, Jie Zhang · Tongji University
Figure 1. Biomarker-defined risk groups in CKM stage 2.Observed six-year risks are shown as a risk ladder for incident CVD, death, and CVD or death; point size reflects subgroup size and horizontal bars show…
Open the figure at full size
Figure 1. Biomarker-defined risk groups in CKM stage 2.Observed six-year risks are shown as a risk ladder for incident CVD, death, and CVD or death; point size reflects…Biomarker-defined risk groups in CKM stage 2.Observed six-year risks are shown as a risk ladder for incident CVD, death, and CVD or death; point size reflects subgroup size and horizontal bars show 95% CIs.Sun et al.
Preprint: cohort study of 6,205 older adults with CKM stage 2, against participants with higher NT-proBNPBiomarkers

6,488 eligible participants

Limit: Cardiovascular disease was identified from self-reported physician diagnoses, leaving events vulnerable to reporting errors

Edited by Boris Djordjevic · AgingResearch.News

Paper
Follow

An observational cohort study analyzed 6,488 adults aged 50 or older without cardiovascular disease, which affects the heart and blood vessels. Researchers used 2016 blood measurements from the Health and Retirement Study and follow-up through 2022. The main analysis covered 6,205 people classified as cardiovascular-kidney-metabolic stage 2, a category of risks involving the heart, kidneys and the body's use of energy.

Six-year risk of cardiovascular disease or death was 15.9% with NT-proBNP, a blood marker of heart strain, below 125 picograms per milliliter, versus 44.0% at or above that level. Among people below this cutoff, higher TNFR1, a protein involved in inflammation, identified a subgroup with greater risk: 27.5% versus 13.5%. The authors suggested these markers may help refine risk assessment within stage 2.

Why it matters

For adults aged 50 or older with stage 2 and no cardiovascular disease, the study addressed whether blood measurements could make a broad health-risk category more useful for assessing six-year risk of cardiovascular disease or death.

Caveats

This observational study did not test whether using the markers to guide care improved outcomes, and the preprint has not been peer-reviewed. The main analysis concerned adults aged 50 or older with stage 2 and no cardiovascular disease, not younger people or those with existing cardiovascular disease.

From the paper

Participants

Among 6,488 eligible participants, 6,205 (95.6%) were classified as measured CKM stage 2.

Results

Events by group

Within this group, participants with NT-proBNP < 125 pg/mL had lower six-year risk of cardiovascular disease or death than those with NT-proBNP > = 125 pg/mL (15.9% vs 44.0%).

Results

Quoted word for word from the full text on researchsquare.com.

Comments

Be the first to comment.

More on Cardiovascular disease